B
Brandon G. Bentz
Researcher at University of Utah
Publications - 35
Citations - 1888
Brandon G. Bentz is an academic researcher from University of Utah. The author has contributed to research in topics: Epidermoid carcinoma & Radiation therapy. The author has an hindex of 19, co-authored 35 publications receiving 1784 citations. Previous affiliations of Brandon G. Bentz include Memorial Sloan Kettering Cancer Center & Huntsman Cancer Institute.
Papers
More filters
Journal ArticleDOI
SDH5, a Gene Required for Flavination of Succinate Dehydrogenase, Is Mutated in Paraganglioma
Huai Xiang Hao,Oleh Khalimonchuk,Margit Schraders,Noah Dephoure,Jean-Pierre Bayley,Henricus P. M. Kunst,Peter Devilee,Cor W. R. J. Cremers,Joshua D. Schiffman,Brandon G. Bentz,Steven P. Gygi,Dennis R. Winge,Hannie Kremer,Jared Rutter +13 more
TL;DR: A combination of bioinformatics, yeast genetics, biochemistry, and human genetics was used to show that a previously uncharacterized mitochondrial protein (Sdh5) is required for the activity of respiratory complex II, leading to the discovery of a human tumor susceptibility gene.
Journal ArticleDOI
Masses of the salivary gland region in children.
TL;DR: Vascular lesions outnumber solid tumors of the salivary gland region and the overall prognosis is favorable, although certain solid salivaries may demonstrate locally aggressive behavior.
Journal ArticleDOI
Head and neck soft tissue sarcomas: a multivariate analysis of outcomes.
Brandon G. Bentz,Bhuvanesh Singh,James M. Woodruff,Murray F. Brennan,Jatin P. Shah,Dennis H. Kraus +5 more
TL;DR: Size >5 cm and high-grade histology are considered poor prognostic indicators and patients with either of these characteristics should be considered for adjuvant trials.
Journal ArticleDOI
Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
TL;DR: Using RT alone with doses of less than 40 Gy did not result in clinically significant hearing loss and high-frequency SNHL was profoundly damaged in patients who received concomitant cisplatin when doses of 100 mg/m(2) were used.
Journal ArticleDOI
Comparison of Whole-Body PET/CT, Dedicated High-Resolution Head and Neck PET/CT, and Contrast-Enhanced CT in Preoperative Staging of Clinically M0 Squamous Cell Carcinoma of the Head and Neck
Rosana Souza Rodrigues,Fernando A. Bozza,Paul E. Christian,John M. Hoffman,Regan Butterfield,Carl R. Christensen,Marta E. Heilbrun,Richard H. Wiggins,Jason P. Hunt,Brandon G. Bentz,Ying J. Hitchcock,Kathryn A. Morton +11 more
TL;DR: The primary advantage of the dedicated HN PET/CT protocol over the WB protocol or CECT in the staging of head and neck cancer is in the detection of small lymph node metastases.